DISA (SGX:532) has entered into a non-binding agreement to acquire 50% of an operator of a rheumatism and arthritis specialist medical center, according to a Monday filing on the Singapore Exchange.
The SG$5.5 million proposed acquisition involves a cash payment of SG$3 million and SG$2.5 million in newly issued DISA shares, priced at either the prevailing market price or a minimum that will be determined later.
The target company, established in 2003, is Singapore's only heartland-based center specializing in arthritis and rheumatism care, with FY24 revenue of SG$7.6 million and EBITDA of SG$2.1 million.
Completion depends on due diligence, funding, and approvals, with the seller committing to a 10-year practitioner role and maintaining a 50% stake.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。